The Radius Health Inc (RDUS) Sees Large Growth in Short Interest

The Radius Health Inc (RDUS) Sees Large Growth in Short Interest

RDUS has been the subject of several research analyst reports. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, April 26th. Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the stock a “buy” rating in a report on Monday, May 22nd. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a report on Friday, April 28th. Maxim Group set a $24.00 target price on shares of Radius Health and gave the stock a “sell” rating in a report on Wednesday, May 24th. Finally, HC Wainwright reissued a “buy” rating and set a $66.00 price objective (down previously from $71.00) on shares of Radius Health in a report on Friday, March 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Radius Health presently has a consensus rating of “Hold” and an average price target of $56.83.

Radius Health Inc (NASDAQ:RDUS) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 10,237,119 shares, an increase of 26.7% from the April 28th total of 8,080,441 shares. Approximately 26.1% of the company’s shares are short sold. Based on an average trading volume of 1,426,182 shares, the short-interest ratio is presently 7.2 days.

Shares of Radius Health (NASDAQ:RDUS) opened at 35.08 on Monday. Radius Health has a 12 month low of $31.58 and a 12 month high of $59.88. The firm’s market capitalization is $1.52 billion. The company has a 50 day moving average of $36.31 and a 200-day moving average of $41.35. Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.18) by $0.14. During the same quarter in the previous year, the company posted ($0.94) earnings per share. Analysts predict that Radius Health will post ($4.42) EPS for the current year.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 61,721 shares of Radius Health stock in a transaction on Wednesday, March 15th. The stock was purchased at an average cost of $39.97 per share, for a total transaction of $2,466,988.37. Following the completion of the purchase, the insider now directly owns 4,415,930 shares of the company’s stock, valued at $176,504,722.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Growth N. V. Biotech acquired 15,000 shares of Radius Health stock in a transaction dated Friday, May 12th. The stock was purchased at an average price of $34.00 per share, with a total value of $510,000.00. Following the completion of the purchase, the insider now directly owns 4,873,799 shares of the company’s stock, valued at approximately $165,709,166. The disclosure for this purchase can be found here. Over the last three months, insiders bought 678,400 shares of company stock worth $24,321,465. 16.80% of the stock is currently owned by insiders. Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after buying an additional 2,628,070 shares during the last quarter. State Street Corp boosted its position in shares of Radius Health by 58.9% in the fourth quarter. State Street Corp now owns 1,885,161 shares of the biopharmaceutical company’s stock worth $71,694,000 after buying an additional 699,023 shares during the last quarter. Arrowgrass Capital Partners US LP bought a new position in shares of Radius Health during the third quarter worth about $32,342,000. Norges Bank bought a new position in shares of Radius Health during the fourth quarter worth about $13,519,000. Finally, Perceptive Advisors LLC acquired a new position in Radius Health during the fourth quarter valued at $10,035,000. Institutional investors own 95.84% of the company’s stock.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 61,721 shares of Radius Health stock in a transaction on Wednesday, March 15th. The stock was purchased at an average cost of $39.97 per share, for a total transaction of $2,466,988.37. Following the completion of the purchase, the insider now directly owns 4,415,930 shares of the company’s stock, valued at $176,504,722.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Growth N. V. Biotech acquired 15,000 shares of Radius Health stock in a transaction dated Friday, May 12th. The stock was purchased at an average price of $34.00 per share, with a total value of $510,000.00. Following the completion of the purchase, the insider now directly owns 4,873,799 shares of the company’s stock, valued at approximately $165,709,166. The disclosure for this purchase can be found here. Over the last three months, insiders bought 678,400 shares of company stock worth $24,321,465. 16.80% of the stock is currently owned by insiders. About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:RDUS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment